MedTrace Logo

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

NCT00056875 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-25

No results posted yet for this study

Summary

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Conditions

Interventions

DRUG

recombinant human keratinocyte growth factor

Sponsors & Collaborators

Principal Investigators

  • John Levine, MD · Univeristy of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056875 on ClinicalTrials.gov